NCT06076642 - A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 4, 2024

Primary Completion Date

January 15, 2029

Study Completion Date

January 15, 2029

Conditions

Primary Immunodeficiency Diseases (PID)

Interventions

BIOLOGICAL

TAK-881

Participants will receive SC infusion of TAK-881.

DEVICE

SC Investigational Needle Sets

The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.

Trial Locations (5)

10461

RECRUITING

Montefiore Medical Center, The Bronx

27705

RECRUITING

Duke Asthma, Allergy and Airway Center, Durham

31201

RECRUITING

Central Georgia Infectious Disease Consultants, Macon

61761

RECRUITING

Sneeze, Wheeze, & Itch Associates, LLC, Normal

75230

RECRUITING

Allergy Partners of North Texas, Dallas